Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.